This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bajetta, E., Ferrari, L., Merlonetti, A., Celio, L., Procopio, G. Artale, S., Zilembo, N., Di Bartolomeo, M. Serregni, E., Bombardieri, E., 1999, Chromogranin A, neuronspecific enolase, carcinoembryonic antigen and hydroxi indole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858–865.
Belaiche, J., Delwaide, J., Vivario, M., Gast, P., Louis, E., and Boniver, J., 1993, Fundic argyrophil cell hyperplasia in atrophic gastritis: a search for a sensitive diagnostic method. Acta Gastroenterol. 56: 11–17.
Colombo, P, A. G. Siccardi, G. Paganelli, P. Magnani, C. Songini, R. Buffa, G. Faglia, and F. Fazio. Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours ofthe pituitary region. Eur. J. Endocrinol. 135:216–221, 1996.
Cryer, P.E., Wortsman, J., Shah, S.D., Nowak, R.M., and Deftos, L.J., 1991, Plasma chromogranin A as marker of sympathochromaffin activity in humans. Am. J. Physiol. 260: E243–E246.
D’Adda, T., Corleto, V., Pilato, F.P., Baggi, M.T., Robutti, F., Delle Fave, G., 1990, Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Gastroenterol. 99: 17–26.
Deftos, L.J., 1991, Chromogranin A, its role in endocrine function and as an endocrine and neuroendocrine tumor marker. EndocrineReview 12: 181–187.
Deftos, L.J., Gazdar, A.F., Hogue-Angeletti, R, Mullen, P.S., and Burton, D.W., 1990, Distinct patterns of chromogranin A-related species can be demonstrated in endocrine cells. Bone Mineral 9: 169–178.
Deftos, L.J., Nakada, S., Burton, D.W., di Sant’Agnese, P.A.. Cockett, A.T., and Abrahamsson, P.A., 1996, Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma ofthe prostate. Urology 48: 58–62.
Elias, A.N., Wilson, A.F., Pandian, M.R., and Kayaleh, R., 1992, Chromogranin A concentrations in plasma of physically active men after acute exercise. Clin. Chem. 38: 2348–2349.
Eriksson, B., Amberg, H., Öberg, K., et al, 1990, A plyclonal antiserum against chromogranin a and B—a new sensitive marker for neuroendocrine tumours. Acta Endocrinology 122: 145–155.
Gould, V.E., Lee, I., and Warren, W.H., 1988, Immunohistochemical evaluation of neuroendocrine cells and neoplasms ofthe lung. Pathol. Res. Practice 183:200–213.
Granberg, D., Stridsberg, M., Seensalu, R., Eriksson, B., Lundqvist, G., Öberg, K., and Skogseid, B., 1999, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 84: 2712–2717.
Hamada, Y., Oishi, A., Shoji, T., Takada, H., Yamamura, M., Hioki, K., and Yamamoto. M., 1992, endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 69: 2641–2646.
Hsiao, R.J., Neumann, H.P.H., Parmer, R.J., Barbosa, J.A. and O’Connor, D.T., 1990, Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am. J. Med. 88: 607–613.
Iacangelo, A.L., and Eiden, L.E., 1995, chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul. Pept. 58: 65–88.
Janson, E.T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., and Öberg, K., 1997, Carcinoid tumors. Analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Onc. 8: 685–690.
Kadmon, D., Thompson, T.C., Lynch, G.R., and Scardino, P.T., 1991, Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol. 146: 358–361.
Larsson, L., Alumets, J., Eriksson, B., Hækansson, R., Lundqvist, G., Öberg, K., and Sundler, F., 1992, Antiserum directed against chromogranin A and B (CAB) is a useful marker for peptide hormone-producing endocrine cells and tumors. Endocr. Pathol., 3: 14–22.
Nobels, F.R.E., Kwekkeboom, D.J., Coopmans, W., Schoenmakers, C.H.; Lindemans, J.; De Herder, W.W.; Krenning, E.P.; Bouillon, R.; Lamberts, S.W., 1997, Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 82:2622–2628.
Nobels, F.R.E., de Herder, W.W., Kwekkeboom, D.J., Coopmans, W.; Mulder, A.; Bouillon, R.; Lamberts, S.W.J. et al, 1994, Serum chromograninA in the differential diagnosis of Cushing’s syndrome. Eur. J. Endocrinol. 131: 589–593.
O’Connor, D.T., Burton, D., and Deftos, L.J., 1983, Immunoreactive chromogranin A in diverse polypeptide hormone producing tumors and normal endocrine tissues. J. Clin. Endocrinol. Metab. 57: 1084–1086.
Pour, P.M., Permert, J., Mogaki, M., Fujii, H., and Kazakoff, K., 1993, Endocrine aspects of exocrine cancer of the pancreas. Their patterns and suggested biologic significance. Am. J. Clin. Pathol. 100: 223–230.
Sanduleanu, S., Stridsberg, M., Jonkers, D., Hameeteman, W., Biemond, I., Lundqvist, G., Lamers, C., and Stockbrugger, R. W., 1999, Serum gastrin and chromogranin A during meal. Aliment. Pharmacol. Ther 13: 145–153
Stabile, B.E., Howard, T.J., Passaro, E., and O’Connor, D.T., 1990, Source of plasma Chromogranin-A elevation in gastrinoma patients. Arch. Surgery 125: 451–453.
Stridsberg, M., Oberg, K., Li, Q., Engstrom, U., and Lundqvist, G., 1995, Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J. Endocrinol. 144: 49–59.
Stridsberg, M., and Husebye, E.S., 1997, Chromogranin A and chromogranin B are sensitive circulating markers for pheochromocytoma. Eur.J. Endocrinol. 136: 67–73.
Sundaresan, V., Reeve, J.G., Stenning, S., Stewart, S., and Bleehen, N.M., 1991, Neuro-endocrine differentiation and clinical behaviour in non-small cell lung tumors. Brit. J. Cancer 64: 333–338.
Syversen, U., Mignon, M., Bonfils, S., Kristensen, A., and Waldum, H.L., 1993, Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol. 32: 161–165.
Syversen, U., Halvorsen, T., Marvik, R., and Waldum, H.L., 1995, Neuroendocrine differentiation in colorectal carcinomas. Eur. J. Gastroenterol. Hepatol. 7: 667–614.
Takiyyuddin, M.A., Cervenka, J.H., Pandian, M.R., Stuenkel, C.A., Neumann, H.P.H., and O’Connor, D.T., 1990, Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J. Clin. Endocrinol. Metab. 71: 360–369.
Wassberg, E., Stridsberg, M., and Christofferson, R., 1996, Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J. Endocrinol. 151: 225–230
Wiedenmann, B., and Huttner, W.B., 1989, Synaptophysin and chromogranins/secretogranins-widespread constutuents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol. 58: 95–121.
Winkler, H., and Fischer-Colbrie, B., 1992, The chromogranins A and B, the first 25 years and future perspectives. Neurosci. 49: 497–528.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Oberg, K., Stridsberg, M. (2002). Chromogranins as Diagnostic and Prognostic Markers in Neuroendocrine Tumours. In: Helle, K.B., Aunis, D. (eds) Chromogranins. Advances in Experimental Medicine and Biology, vol 482. Springer, Boston, MA. https://doi.org/10.1007/0-306-46837-9_26
Download citation
DOI: https://doi.org/10.1007/0-306-46837-9_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46446-1
Online ISBN: 978-0-306-46837-7
eBook Packages: Springer Book Archive